CDIO (Cardio Diagnostics) יחס שווי שוק לשווי בספרים

Cardio Diagnostics AI tests for combating ischemia are generating stable B2B demand, as evidenced by the company's valuation history via the P/B ratio, where the metric stands at 0.67. However, challenges with insurance reimbursements and slow technology adoption are hindering the payback period. Meanwhile, expansion into the telemedicine and corporate wellness segments opens broad prospects for growing the customer base.

This indicator compares the market value of the business with its net assets to determine the extent of the issuer's overvaluation. The calculation reveals the gap between exchange expectations and the company's actual capital. By analyzing the price-to-book ratio, an investor separates speculative noise from the fundamental base. For Cardio Diagnostics (CDIO), this is critical due to high marketing costs and clinical data expenses. The metric reflects the degree to which the market is willing to overlook insurance payout risks.